恩考拉非尼联合比美替尼治疗BRAFV600突变转移性非小细胞肺癌的II期开放标签研究
这项正在进行的开放标签单臂II期研究评估恩考拉非尼联合比美替尼治疗BRAFV600E突变转移性非小细胞肺癌的疗效与安全性。98例患者(59例初治、39例经治)接受口服恩考拉非尼450mg每日一次联合比美替尼45mg每日两次,28天为一周期。独立影像学评估的确认客观缓解率在初治患者为75%(95%CI 62-85),经治患者为46%(95%CI 30-63);安全性特征与黑色素瘤中已获批适应症所见一致。
要点
- 经治患者客观缓解率46%,中位缓解持续时间16.7个月
- 初治患者客观缓解率75%,中位无进展生存期不可估计
- 最常见治疗相关不良事件为恶心(50%)、腹泻(43%)和疲乏(32%)
核心结论
- 对于初治和经治的BRAFV600E突变转移性非小细胞肺癌患者,恩考拉非尼联合比美替尼显示出有意义的临床获益,安全性特征与黑色素瘤已获批适应症中所见一致。
研究设计与样本
- 正在进行的开放标签、单臂、II期研究。
- 98例BRAFV600E突变转移性非小细胞肺癌患者接受口服恩考拉非尼450mg每日一次联合比美替尼45mg每日两次,28天为一周期。
- 主要终点为独立影像学评估确认的客观缓解率。
- 次要终点包括缓解持续时间、疾病控制率、无进展生存期、总生存期、至缓解时间和安全性。
主要发现
- 初治患者客观缓解率为75%(95%CI 62-85),经治患者为46%(95%CI 30-63)。
- 初治患者中位缓解持续时间不可估计(95%CI 23.1至不可估计),经治患者为16.7个月(95%CI 7.4至不可估计)。
- 24周时疾病控制率初治患者为64%,经治患者为41%。
- 初治患者中位无进展生存期不可估计(95%CI 15.7至不可估计),经治患者为9.3个月(95%CI 6.2至不可估计)。
- 最常见的治疗相关不良事件为恶心(50%)、腹泻(43%)和疲乏(32%);24例(24%)患者因治疗相关不良事件减量,15例(15%)永久停用恩考拉非尼联合比美替尼;报告1例5级治疗相关不良事件为颅内出血。
临床怎么用
- 原文未据此给出推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAFV600E/K-mutant metastatic melanoma. We evaluated the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600E-mutant metastatic non-small-cell lung cancer (NSCLC). METHODS: In this ongoing, open-label, single-arm, phase II study, patients with BRAFV600E-mutant metastatic NSCLC received oral encorafenib 450 mg once daily plus binimetinib 45 mg twice daily in 28-day cycles. The primary end point was confirmed objective response rate (ORR) by independent radiology review (IRR). Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival, time to response, and safety. RESULTS: At data cutoff, 98 patients (59 treatment-naïve and 39 previously treated) with BRAFV600E-mutant metastatic NSCLC received encorafenib plus binimetinib. Median duration of treatment was 9.2 months with encorafenib and 8.4 months with binimetinib. ORR by IRR was 75% (95% CI, 62 to 85) in treatment-naïve and 46% (95% CI, 30 to 63) in previously treated patients; median DOR was not estimable (NE; 95% CI, 23.1 to NE) and 16.7 months (95% CI, 7.4 to NE), respectively. DCR after 24 weeks was 64% in treatment-naïve and 41% in previously treated patients. Median PFS was NE (95% CI, 15.7 to NE) in treatment-naïve and 9.3 months (95% CI, 6.2 to NE) in previously treated patients. The most frequent treatment-related adverse events (TRAEs) were nausea (50%), diarrhea (43%), and fatigue (32%). TRAEs led to dose reductions in 24 (24%) and permanent discontinuation of encorafenib plus binimetinib in 15 (15%) patients. One grade 5 TRAE of intracranial hemorrhage was reported. Interactive visualization of the data presented in this article is available at the PHAROS dashboard (https://clinical-trials.dimensions.ai/pharos/). CONCLUSION: For patients with treatment-naïve and previously treated BRAFV600E-mutant metastatic NSCLC, encorafenib plus binimetinib showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma.
引用
- Riely GJ, Smit EF, Ahn MJ, et al. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2023. PMID: 37270692. doi:10.1200/JCO.23.00774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。